BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational HighlightsGlobeNewsWire • 03/09/23
BioXcel Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023GlobeNewsWire • 02/23/23
BioXcel Therapeutics Announces Positive Full Data from Phase 2 Trial of BXCL701 in Rare, Aggressive Form of Prostate Cancer; to be Presented at 2023 ASCO Genitourinary Cancers SymposiumGlobeNewsWire • 02/13/23
BioXcel Therapeutics to Host BXCL701 Key Opinion Leader Day to Highlight Company's Investigational, Oral Innate Immune Activator for Rare Form of Prostate CancerGlobeNewsWire • 02/08/23
BioXcel Therapeutics Announces Promising Top-Line Results from Phase 2 Trial of BXCL701 in Aggressive Form of Rare Prostate CancerGlobeNewsWire • 01/11/23
BioXcel Therapeutics to Present at 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/22/22
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer's DiseaseGlobeNewsWire • 12/19/22
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap ConferenceGlobeNewsWire • 12/01/22
BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or SchizophreniaGlobeNewsWire • 11/30/22
Seeking Treatment For Agitation In Alzheimer's Patients: A Race For A Multi-Billion Opportunity, And BioXcel's BXCL501 Has The EdgeSeeking Alpha • 11/14/22
BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational HighlightsGlobeNewsWire • 11/10/22
BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022GlobeNewsWire • 10/27/22
BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/09/22
BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational HighlightsGlobeNewsWire • 08/09/22